Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Unknown 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Neoplasm Metastasis 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Recurrence 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Interferon-alpha × Clear all
NCT00003715 2015-12-03

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

AVAX Technologies

Phase 2 Terminated
425 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡